ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer

Tzu-Ting Huang; Erika J. Lampert; Cynthia Coots; Jung-Min Lee
Cancer Treatment Reviews2020DOI: 10.1016/j.ctrv.2020.102021
6阅读
引用收藏
分享

摘要

Abstract(#br)Ovarian cancer is the most lethal gynecological malignancy worldwide although exponential progress has been made in its treatment over the last decade. New agents and novel combination treatments are on the horizon. Among many new drugs, a series of PI3K/AKT/mTOR pathway (referred to as the PI3K pathway) inhibitors are under development or already in clinical testing. The PI3K pathway is frequently upregulated in ovarian cancer and activated PI3K signaling contributes to increased cell survival and chemoresistance. However, no significant clinical success has been achieved with the PI3K pathway inhibitor(s) to date, reflecting the complex biology and also highlighting the need for combination treatment strategies. DNA damage repair pathways have been active therapeutic targets in ovarian cancer. Emerging data suggest the PI3K pathway is also involved in DNA replication and genome stability, making DNA damage response (DDR) inhibitors as an attractive combination treatment for PI3K pathway blockades. This review describes an expanded role for the PI3K pathway in the context of DDR and cell cycle regulation. We also present the novel treatment strategies combining PI3K pathway inhibitors with DDR blockades to improve the efficacy of these inhibitors for ovarian cancer.

学科与关键词

关键词
PI3K/AKT/mTOR pathwayDNA damage responseCell cycle checkpointDNA repairOvarian cancer
相关
加载中…
  • Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors
    Kasun, Wanigasooriya; Robert, Tyler; Joao D., Barros-Silva; Yashashwi, Sinha; Tariq, Ismail; Andrew D., BeggsCancers, 2020, 12(5): 1278.被引 7
  • Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
    Tang, Bin; Wu, Min; Zhang, Lin; Jian, Shuyi; Lv, Shiyi; Lin, Tongyuan; Zhu, Shuangshuang; Liu, Layang; Wang, Yixue; Yi, Zhengfang*; Jiang, Feiyun*Frontiers in Oncology, 2023, 13: 1154073.被引 2
  • Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
    Guo, Chong; Song, Chaoying; Zhang, Jiali; Gao, Yisong; Qi, Yuying; Zhao, Zongyao; Yuan, Chengfu*Genes & Diseases, 2022, 9(3): 668-681.被引 10
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Treatment Reviews
发表日期
2020
卷期
第 86 卷
DOI
10.1016/j.ctrv.2020.102021
成果收录
CHINAJOURNAL

作者

  • T

    Tzu-Ting Huang (第一作者)

  • E

    Erika J. Lampert

查看全部 4 位作者收起作者
  • C

    Cynthia Coots

  • J

    Jung-Min Lee

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417